4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Other_reagents > Adipogen/BBT594/SYN-1225-M005/5 mg
商品详细Adipogen/BBT594/SYN-1225-M005/5 mg
Adipogen/BBT594/SYN-1225-M005/5 mg
Adipogen/BBT594/SYN-1225-M005/5 mg
商品编号: SYN-1225-M005
品牌: Adipogen Inc
市场价: ¥8420.00
美元价: 5052.00
产地: 美国(厂家直采)
公司:
产品分类: 其他试剂
公司分类: Other_reagents
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
More Information
Product Details
Synonyms BBT-594
Product Type Chemical
Properties
Formula C28H30F3N7O3
MW 569.6
CAS 882405-89-2
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by SynKinase.
Other Product Data Target: JAK2 | Kinase Group: PTK | Substrate: Tyrosine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key VQLNKQZLPGLOSI-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
BBT594 (NVP-BBT594) is a potent and selective inhibitor of RET and JAK2. BBT594 impairs "glial-derived neurotrophic factor" (GDNF)-RET signaling and GDNF-dependent growth in specific in vitro models. Direct inhibition of GDNF-RET signaling by BBT594 in ER+ breast cancer cells enhances the sensitivity to aromatase inhibitor (AI) treatment and reverts AI resistance. In murine models, the IC50 of BBT594 on JAK2 inhibition varies between 8nM - 29nM, depending on the cell model and abundant JAK2 mutations.
Product References
  1. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent: R. Andraos, et al.; Cancer Discov. 2, 512 (2012)
  2. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors: A. Morandi, et al.; Cancer Res. 73, 3783 (2013)
品牌介绍
Adipogen公司由三个子公司组成,分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国,运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发,如癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外,也可提供抗体和蛋白产品,Adipogen拥有自己的化学实验室,致力于开发创新型小分子化合物。